About this trial
The purpose of is study is to investigate whether ischemic postconditioning (iPOST) and intravascular ultrasound-guided (IVUS) percutaneous coronary intervention (PCI) improve the clinical outcome of patients with ST-segment elevation myocardial infarction treated with primary PCI.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥18 years
Acute onset of chest pain with <12 hours duration
STEMI as characterized by 2 mm ST elevation in 2 or more V1 through V4 leads or presumed new left bundle branch block with minimum of 1 mm concordant ST elevation or 1 mV ST-segment elevation in the limb lead (II, III and aVF, I, aVL) and V4-V6 or ST depression in 2 or more V1 through V4 leads indicating posterior AMI.
Disqualifiers
None
Trial design
Factorial
Treatments tested in this trial
PCI + Ischemic conditioning
Procedure/SurgeryIPOST is repeated for 4 cycles (60 sec obstruction followed by 60 sec perfusion each) and followed by stent implantation with a 1.1/1.0 ratio of stent diameter/reference vessel diameter and a stent length sufficient to cover the entire lesion from healthy to healthy area of the vessel. During the first cycle of re-occlusion of full vessel occlusion is secured by a small injection of contrast.
Stent with ultrasound
Procedure/SurgeryIVUS catheters are to be advanced at least 20 mm distal to the culprit lesion. After administration of intracoronary nitroglycerine, an IVUS-pullback is to be performed at 0.5mm/second using a commercially available imaging system. Stent size and landing zones are decided based on the IVUS.
Treatment groups
Trial outcomes
Primary outcomes
iPOST
Number of participants that experience all-cause mortality or hospitalization for heart failure
iSTEMI (IVUS)
Number of participants that experience all-cause mortality, unplanned ischemia-driven revascularization and new myocardial infarction
Secondary outcomes
iSTEMI (IVUS)
Target vessel failure (cardiac mortality, unplanned ischemia driven target vessel revascularization or target vessel myocardial infarction
iSTEMI (IVUS)
Individual components of the primary endpoint
iSTEMI (IVUS)
Cardiac mortality
iSTEMI (IVUS)
Unplanned ischemia driven target vessel revascularization
Other outcomes
iSTEMI (IVUS)
Hospitalization for heart failure
iSTEMI (IVUS)
Stroke
iSTEMI (IVUS)
Bleeding
iSTEMI (IVUS)
Quality of life
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Thomas Engstrom
Lead sponsor
Rigshospitalet, Denmark
Sponsor institution